Mitsubishi UFJ Asset Management Co. Ltd. Has $213,000 Stake in Novavax, Inc. (NASDAQ:NVAX)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Novavax, Inc. (NASDAQ:NVAX) by 9.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,169 shares of the biopharmaceutical company’s stock after buying an additional 2,780 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Novavax were worth $213,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Federated Hermes Inc. lifted its holdings in Novavax by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 50,506 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 2,124 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in Novavax by 16.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,126 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 2,287 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Novavax during the 4th quarter worth approximately $27,000. Monaco Asset Management SAM lifted its holdings in Novavax by 1.8% during the 1st quarter. Monaco Asset Management SAM now owns 290,000 shares of the biopharmaceutical company’s stock worth $1,859,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Novavax by 3.3% during the 1st quarter. Rhumbline Advisers now owns 215,413 shares of the biopharmaceutical company’s stock worth $1,381,000 after purchasing an additional 6,949 shares during the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Price Performance

Novavax stock opened at $9.43 on Friday. Novavax, Inc. has a one year low of $5.01 and a one year high of $15.22. The stock’s fifty day moving average price is $7.11 and its two-hundred day moving average price is $7.19. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The firm has a market cap of $1.53 billion, a PE ratio of 4.14, a price-to-earnings-growth ratio of 0.10 and a beta of 2.50.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%. The company had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. During the same quarter last year, the company posted $0.99 EPS. The company’s revenue for the quarter was down 42.4% compared to the same quarter last year. As a group, research analysts expect that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVAX has been the subject of several research reports. Citigroup started coverage on Novavax in a report on Tuesday, June 17th. They set a “sell” rating and a $6.00 price target for the company. B. Riley restated a “buy” rating on shares of Novavax in a research note on Monday, May 19th. JPMorgan Chase & Co. lowered their price objective on Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a research note on Friday, May 9th. Finally, Bank of America lowered their price objective on Novavax from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 22nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $15.86.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.